Status:
COMPLETED
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
Up to 120 years
Brief Summary
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may als...
Detailed Description
OBJECTIVES: * Determine the qualitative and quantitative expression of OX-40 and related markers in sentinel lymph nodes previously removed from patients with cancer. * Determine the qualitative and ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed cancer, including, but not limited to, the following:
- Melanoma
- Breast cancer
- Invasive squamous cell cancer
- Other cancers for which patients underwent or will undergo the following:
- Adequate archived paraffin-embedded tissue for making slides for immunostaining
- Adequate freshly removed sentinel lymph node (and primary tumor, if available) tissue for laboratory assays
- Clinical data and date of last follow-up on tumor stage and status must be available
- Hormone receptor status not specified
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00900302
Start Date
April 1 2005
End Date
March 1 2011
Last Update
February 10 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239-3098